Combined Receptor Antagonist Stimulation of the Hypothalamic-Pituitary-Adrenal Axis Test Identifies Impaired Negative Feedback Sensitivity to Cortisol in Obese Men
Open Access
- 1 April 2009
- journal article
- research article
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 94 (4), 1347-1352
- https://doi.org/10.1210/jc.2008-2054
Abstract
Context: Hypothalamic-pituitary-adrenal (HPA) axis dysregulation may underlie disorders including obesity, depression, cognitive decline, and the metabolic syndrome. Conventional tests of HPA axis negative feedback rely on glucocorticoid receptor (GR) agonists such as dexamethasone but do not test feedback by endogenous cortisol, potentially mediated by both GR and mineralocorticoid receptors (MR). Objective: The objective of the study was to use a combination of GR (RU38486, mifepristone) and MR (spironolactone) antagonists to explore the poorly understood activation of the HPA axis that occurs in obesity. Design: This was a double-blind, placebo-controlled, randomized, crossover study. Setting: The study was conducted at a clinical research facility. Participants: Participants included 15 lean (body mass index 22.0 ± 1.6 kg/m2) and 16 overweight/obese (body mass index 30.1 ± 3.5 kg/m2) men. Intervention: Subjects attended on four occasions for blood and saliva sampling every 30 min between 1800 and 2200 h. At 1100 and 1600 h before visits, subjects took 200 mg spironolactone, 400 mg RU38486, 200 mg spironolactone + 400 mg RU38486, or placebo orally. Main Outcome Measures: Serum cortisol levels after drug or placebo were measured. Results: Cortisol levels did not differ between lean and obese after placebo. Spironolactone and RU38486 alone had modest effects, increasing cortisol by less than 50% in both groups. However, combined spironolactone plus RU38486 elevated cortisol concentrations substantially, more so in lean than obese men [2.9- (0.3) vs. 2.2 (0.3)-fold elevation, P = 0.002]. Conclusions: Combined receptor antagonist stimulation of the HPA axis reveals redundancy of MR and GR in negative feedback in humans. Obese men have impaired responses to combined receptor antagonist stimulation, suggesting impaired negative feedback by endogenous cortisol. Such an approach may be useful to dissect abnormal HPA axis control in neuropsychiatric and other disorders.Keywords
This publication has 27 references indexed in Scilit:
- Glucocorticoids and Cardiovascular DiseaseActa Endocrinologica, 2007
- 11β-Hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabeticsProceedings of the National Academy of Sciences of the United States of America, 2004
- The Stimulatory Effect of Canrenoate, a Mineralocorticoid Antagonist, on the Activity of the Hypothalamus-Pituitary-Adrenal Axis Is Abolished by Alprazolam, a Benzodiazepine, in HumansJournal of Clinical Endocrinology & Metabolism, 2002
- Increased activity of the hypothalamus–pituitary–adrenal system after treatment with the mineralocorticoid receptor antagonist spironolactonePsychoneuroendocrinology, 2000
- Mineralocorticoid Receptor also Modulates Basal Activity of Hypothalamus-Pituitary-Adrenocortical System in HumansNeuroendocrinology, 1998
- Dexamethasone and 11-dehydrodexamethasone as tools to investigate the isozymes of 11β-hydroxysteroid dehydrogenase in vitro and in vivoJournal of Endocrinology, 1997
- Glucocorticoid hypersecretion and the age-impaired hippocampus: cause or effect?Journal of Endocrinology, 1995
- Antimineralocorticoid Canrenoate Enhances Secretory Activity of the Hypothalamus-Pituitary-Adrenocortical (HPA) Axis in HumansNeuroendocrinology, 1993
- The New Steroid Analog RU 486 Inhibits Glucocorticoid Action in ManJournal of Clinical Endocrinology & Metabolism, 1984
- RU 486: a steroid with antiglucocorticosteroid activity that only disinhibits the human pituitary-adrenal system at a specific time of day.Proceedings of the National Academy of Sciences of the United States of America, 1984